UPC court fees and recoverable costs announced

Patent Update & Alert

Patent Update & Alert

Court of Appeal upholds invalidity of Rovi patent

The Court of Appeal has upheld the invalidity of a Rovi patent on the grounds of obviousness

08 December 2015
类别: 

Patents Court rejects Warner-Lambert amendment in pregabalin dispute as an abuse of process

The Patents Court has rejected Warner-Lambert’s conditional application to amend its patent relating to pregabalin.

Patents Court upholds validity of atomoxetine ADHD patent

The Patents Court has upheld the validity of a patent directed to the use of atomoxetine for the treatment of ADHD

European Commission releases sixth report on patent settlements in the pharmaceuticals sector

European Commission report on patent settlements in the pharmaceuticals sector warns of competition law concerns but suggests that intervention is unlikely.

H&M bras infringe patent

In a rare patent case in the fashion sector, the Patents Court has decided that three styles of H&M bras infringe a patent relating to the tubular fabric 更多

03 December 2015
类别: 

Patents Court grants declaration to Actavis in pemetrexed dispute

The Patents Court has granted Actavis a declaration in relation to its new pemetrexed product in its dispute with Eli Lilly.

Unitary Patent: Agreement reached on ‘distribution key'

Member states have agreed the distribution of renewal fees for the Unitary Patent.

The UPC and Unitary Patent: How close are we to implementation?

With the UPC expected to be in operation from early 2017, what are the key outstanding issues?

Patents Court grants interim injunction against dealings in full label generic pregabalin

The Patents Court has granted an interim injunction in respect of dealings in full label generic pregabalin products.

Patents Court finds inhaler capsule patent invalid

The Patents Court has decided that a patent relating to capsules used in a dry powder inhaler is invalid.

Patents Court: patent for immunotherapy treatment valid

The Patents Court has rejected a validity attack against a patent relating to immunotherapy treatment for cancer.

A Unitary SPC… and a recalibration?

The Commission confirms it is considering introduction of a Unitary SPC and consider recalibration of the SPC regime.

本网站使用Cookie来增强您的体验并帮助我们改善网站。请参阅我们的隐私政策以获取更多信息。如果您继续浏览网站而不更改设置,我们将假设您愿意收到这些Cookie。您可以随时更改Cookie设置

有关我们使用哪些类型Cookie的更多信息,请参阅我们的Cookie使用政策